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Abstract 
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare but devastating genetic 
disease characterized by segmental premature aging, with cardiovascular disease 
being the main cause of death. Cells from HGPS patients accumulate progerin, a 
permanently farnesylated, toxic form of Lamin A, disrupting nuclear shape and 
chromatin organization, leading to DNA-damage accumulation and senescence. 
Therapeutic approaches targeting farnesylation or aiming to reduce progerin levels 
have provided only partial health improvements. Recently, we identified Remodelin, a 
small-molecule agent that leads to amelioration of HGPS cellular defects through 
inhibition of the enzyme N-acetyltransferase 10 (NAT10). Here, we show preclinical 
data demonstrating that targeting NAT10 in vivo, either via chemical inhibition or 
genetic depletion, significantly enhances cardiac function, fitness and healthspan in a 
LmnaG609G HGPS mouse model. Collectively, the data provided here highlight NAT10 
as a potential therapeutic target for HGPS. 
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Introduction 
The nuclear envelope (NE) provides a dynamic boundary between the inner nuclear 
mass and the cytoplasm, and is critical for normal functioning of the eukaryotic cell. 
Key factors for NE function as a compartmental border are the nuclear lamins, scaffold 
proteins that specify nuclear architecture and provide mechanical strength to the 
nucleus and cell 1. Notably, over the past few years, lamins have emerged as 
significant players in many other critical cellular functions including differentiation, 
intracellular signaling, chromatin organization, transcription, as well as DNA replication 
and repair 2,3. In mammals, the nuclear lamins are categorized in two distinct classes: 
A-type lamins (Lamin A, Lamin C, Lamin C2 and Lamin AΔ10 all encoded by the LMNA 
gene) and B-type lamins (Lamin B1 encoded by LMNB1, and Lamin B2 that, together 
with Lamin B3, are encoded by the LMNB2 gene) 4. 
In accord with their important roles, loss-of-function mutations in lamin genes result in 
genetic syndromes with severe presentations called laminopathies (OMIM #150330; 
#150340; #150341). These include muscular dystrophies (for example, Emery-Dreyfus 
Muscular Dystrophy), peripheral neuropathies (for example, Charcot-Marie Tooth-
Disease), leukodystrophy, lipodystrophy, as well as premature aging (progeria) 
syndromes such as Atypical Werner Syndrome (AWS), Restrictive Dermopathy (RD) 
and Hutchinson Gilford Progeria Syndrome (HGPS) 2,5. Of all these syndromes, HGPS 
is the one with the most striking presentation. 
After onset, usually within the first year of life, HGPS patients start to display short 
stature, low body weight, hair loss, lipodystrophy, scleroderma, decreased mobility, 
osteoporosis, as well as facial features that resemble accelerated aspects of normal 
ageing 6. While cognitive development is normal, cardiovascular abnormalities – 
characterized by medial smooth-muscle cell loss and secondary maladaptive vascular 
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remodeling (intimal thickening, disrupted elastin fibers and deposition of 
atherosclerotic plaques) – are the main reasons for death, with the median life 
expectancy at birth for HGPS patients being 14.6 years 7-10. 
HGPS arises from heterozygous G608G point mutation of LMNA exon 11, leading to 
cryptic mRNA splicing and expression of a shorter, dysfunctional form of Lamin A 
called progerin 11-13. Like wild-type Lamin A, progerin undergoes several post-
translational modifications, including the addition of a farnesyl group required for its 
targeting to the nuclear envelope. However, unlike Lamin A, progerin remains 
permanently farnesylated, causing it to accumulate at the inner nuclear membrane. In 
HGPS cells, progerin acts as a dominant-negative protein, aggregating wild-type 
lamins, disrupting nuclear shape and chromatin organization, and leading to increased 
genomic instability and rapid cell senescence 14,15. While farnesyl-transferase inhibition 
(FTI) 16-20 is being explored as a therapeutic approach for HGPS and has provided 
certain health improvements in patients 21, there is a clear need for additional 
therapeutic regimes 22. Recently, we discovered that a small-molecule compound, 
which we named Remodelin, can ameliorate HGPS cellular phenotypes. Remodelin 
acts in a progerin- and FTI-independent pathway by targeting and inhibiting the N-
acetyltransferase NAT10 23. 
Here, we assess NAT10 inhibition as a potential therapeutic strategy for HGPS by 
using an established mouse model (Lmna - G609G allele) that exhibits premature-
aging phenotypes similar to those of HGPS patients 24. Critical for translating NAT10 
inhibition towards human patients, we show that chemical or genetic targeting of 
NAT10 decreases genomic instability, and improves global healthspan of both 
homozygous and heterozygous HGPS mice. 
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Results 
Remodelin is well tolerated and extends HGPS mouse health  
To determine the effects of Remodelin on HGPS mouse cells, we derived skin 
fibroblasts from LmnaG609G/G609G and wild-type (WT) littermates. As observed in human 
HGPS fibroblasts 25,26, LmnaG609G/G609G fibroblasts displayed nuclear shape defects 
and increased genomic instability as reflected by a higher level of the DNA double-
strand break (DSB) marker γH2AX (Ser-139 phosphorylated histone H2AX), in a 
manner that was abrogated by Remodelin treatment (Fig. 1a, b). These results showed 
that Remodelin treatment can reverse HGPS induced genomic instability and nuclear 
shape defects in mouse cells, and provided us with encouraging preliminary evidence 
to proceed with in vivo studies. To assess Remodelin’s suitability for in vivo studies, 
we initially defined its pharmacokinetic properties in WT mice. Overall, oral (PO) 
delivery appeared the best route of administration (Fig. 1c; Supplementary Fig. 1a; 
Supplementary Table 1-2), with bioavailability of ~44% (Fig. 1c, d) and significant 
accumulation to heart and skeletal muscle (Fig. 1e). Based on these data, WT and 
LmnaG609G/G609G mice were treated with a Remodelin dose of 100 mg per kg orally, on 
a daily schedule from 3 weeks of age onwards, until endpoint. This treatment was well 
tolerated by both genotypes, with no weight loss (Supplementary Fig. 1b) and with 
significant Remodelin being present in the skeletal muscle, liver and brain of the 
LmnaG609G/G609G mice (Supplementary Fig. 1c). Furthermore, in line with a previous 
report that NAT10 promotes melanogenesis 27, we found that Remodelin treatment led 
to hair graying (Supplementary Fig. 1d). As described before, we found that 
LmnaG609G/G609G mice had dramatically shorter healthspans compared to WT controls, 
associated with accelerated body-weight loss (Fig. 1f; Supplementary Table 3) and 
premature-aging phenotypes resembling the human syndrome 24. Notably, Remodelin 
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led to a 25% increase in Kaplan–Meier area under the curve for treated versus vehicle 
treated mice (Fig. 1f; Supplementary Table 3). Together, these data established that 
Remodelin is well tolerated in vivo and can enhance the healthspan of HGPS mice. 
 
Remodelin ameliorates cardiac pathology of HGPS mice  
HGPS clinical presentation involves loss of subcutaneous adipose tissue7 and 
cardiovascular abnormalities, including adventitial fibrosis and medial smooth-muscle 
cell loss with depletion of smooth-muscle actin in the remaining cells 8,9,28,29. These 
cardiovascular features represent major pathologies that contribute to morbidity and 
lethality in HGPS2. Thus, we analyzed these parameters at the level of the skin, aorta 
and coronary heart arteries in Remodelin-treated HGPS mice as compared to vehicle 
treated controls at their respective end-points. Importantly, Remodelin treatment 
significantly reduced the loss of subcutaneous adipose tissue that is seen in the HGPS 
mouse model (Fig. 2a). Moreover, it led to dramatic amelioration of HGPS cardiac 
pathologies, including reduction of adventitial fibrosis of the aorta (Fig. 2b), rescue of 
vascular smooth muscle cell loss (Fig. 2c) and salvage of smooth muscle actin (SMA) 
loss both in the aorta and coronary arteries (Fig. 2d, Supplementary Fig. 2a). By 
contrast, Remodelin treatment had no significant effect on WT mice at a similar age 
(Supplementary Fig. 2b). Furthermore, as observed in mouse and human fibroblasts, 
Remodelin reduced markers of genome instability in both heart and lung tissues of 
LmnaG609G/G609G mice (Fig. 2e, f). Together, these data highlighted how Remodelin 
treatment delayed onset of cardiovascular pathologies that represent the most 
debilitating aspect of HGPS. 
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Engineering and characterization of a Nat10 mouse model 
 To validate NAT10 was the relevant pharmacological target mediating the in vivo 
effects of Remodelin, we engineered a Nat10 knockout mouse model (Supplementary 
Fig. 3a). Bi-allelic Nat10 inactivation was lethal before embryonic day E14.5 (Fig. 3a), 
indicating that NAT10 is critical for mouse development. However, heterozygous 
Nat10+/- mice were born healthy, and were observed to express the Nat10 mRNA and 
protein products at levels ~50% of those in WT animals (Fig. 3b, c). As NAT10 is largely 
uncharacterized and has not been studied in mice before, we performed a broad 
phenotypic analysis of Nat10+/- mice (Supplementary Fig. 3b, c, Supplementary Fig. 4 
and, Supplementary Data file 1). In most regards, Nat10+/- mice were indistinguishable 
from WT (blue color Supplementary Fig. 3b), with the exception of body weight, which 
was consistently lower than that of WT mice despite similar tail-to-nose lengths, 
associated with changes in lean and fat mass, triglycerides and cholesterol levels 
(Supplementary Fig. 3b, Supplementary Fig. 4a). Additional parameters, including 
potassium levels and neutrophil numbers, showed evidence of sexual dimorphism 
(Supplementary Fig. 4b). Moreover, NAT10 reduction triggered gene-expression 
changes in the heart (Fig. 3d, Supplementary Data file 2), with many deregulated 
genes being connected to cellular pathways associated with longevity, such as 
responses to starvation or insulin signaling30 (Supplementary Fig. 3c). Other highly 
enriched pathways deregulated upon NAT10 depletion included regulation of inclusion 
body assembly and protein refolding. These data showed that, while complete NAT10 
knock-out leads to embryonic lethality, NAT10 haploinsufficient mice are born at 
expected frequencies and are overtly healthy, thereby allowing us to explore potential 
impacts of reducing Nat10 gene dosage in the context of a HGPS in vivo genetic 
model. 
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Nat10 haploinsufficiency enhances fitness of progeria mice 
 To explore the interaction between NAT10 and HGPS, we generated two cohorts of 
LmnaG609G/G609G mice: one on a WT Nat10 background (Nat10+/+) and the other 
carrying the Nat10 heterozygous deletion (Nat10+/-). Notably, healthspan analysis 
showed that, as for Remodelin treatment, reduced Nat10 gene dosage significantly 
extended the timeframe of body weight loss of LmnaG609G/G609G by 17% (Fig. 4a; 
Supplementary Table 3). Moreover, as compared to LmnaG609G/G609G animals, 
LmnaG609G/G609GNat10+/- mice displayed a significant delay in the appearance of back 
curvature (Fig. 4b-d) and enhanced fitness, as observed by lower incidence of common 
LmnaG609G/G609G mouse pathologies such as penile prolapse and eye keratitis (data not 
shown). Additionally, LmnaG609G/G609GNat10+/- mice were more active and overtly 
healthier than their age-matched controls (Supplementary Movies 1-3). To better 
understand how HGPS phenotypes were counteracted by NAT10 depletion, we 
performed selected biochemical analyses on mice at 9 and 12 weeks of age. While 
NAT10 depletion had no effects on parameters such as fat mass and cholesterol levels 
of progeria mice, it significantly normalized others, including glycerol and urea levels 
(Supplementary Data file 3). Furthermore, the decrease in heart rate observed in 
LmnaG609G/G609G mice compared to WT controls was significantly circumvented by 
Nat10 depletion at 9 weeks but not at 12 weeks (Fig. 4e), suggesting that the onset of 
heart abnormalities was delayed. Notably, at 12 weeks, p21 expression was increased 
in hearts of LmnaG609G/G609G mice as compared to WT controls, probably reflecting 
higher DNA-damage loads, but not in LmnaG609G/G609GNat10+/- mice (Fig. 4f). While 
LmnaG609G/G609G mice were reported to be infertile 24, under our husbandry they were 
sub-fertile: LmnaG609G/G609G males had decreased sperm counts (Supplementary Fig. 
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5a) but sperm were motile and able to fertilize wild-type oocytes (Supplementary Fig. 
5b). Similarly, LmnaG609G/G609G females produced morphologically normal oocytes that 
were meiotically competent (Supplementary Fig. 5c, d), and super-ovulated eggs from 
LmnaG609G/G609G females could be fertilized by WT sperm (Supplementary Fig. 5b). 
However, while LmnaG609G/G609G females never produced litters, LmnaG609G/G609G males 
could father pups, albeit at a very low frequency and never more than one litter. These 
data suggested that sub-fertility of HGPS mice was caused by decreased reproductive 
fitness rather than by a specific physiological problem. Strikingly, global fitness/health 
improvements associated with reduced Nat10 gene dosage in LmnaG609G/G609GNat10+/- 
mice (Supplementary Movies 2-3) correlated with an enhancement of male and female 
fertility (Supplementary Fig. 5e; 45% in LmnaG609G/G609GNat10+/- versus 21% in 
LmnaG609G/G609G). While we, like others, have used homozygous LmnaG609G/G609G to 
model HGPS, it is important to note that patients carry a heterozygous Lmna mutation, 
leading to expression of both WT Lamin A and progerin. We therefore wished to study 
the effect of reducing Nat10 gene dosage in heterozygous Lmna+/G609G mice. 
Extending upon the previous report showing reduced lifespan of such mice24, we 
performed an extensive phenotypic analysis of Lmna+/G609G mice and found them to 
display similar premature aging phenotypes as the homozygous mutant 
(Supplementary Fig. 6, Supplementary Data file 4), albeit with delayed onset. When 
we assessed the impact of Nat10 heterozygosity in this human-disease model, we 
found that Lmna+/G609GNat10+/- mice had significantly longer healthspan than 
Lmna+/G609GNat10+/+ mice. Indeed, there was a 90 days gap between the longest lived 
LmnaG609G/+Nat10+/- mouse and the longest lived Lmna+/G609GNat10+/+ mouse (Fig. 4g; 
Supplementary Table 3). In addition, the LmnaG609G/+Nat10+/- mice displayed health 
enhancements, such as decreased back curvature (Supplementary Fig. 7).  
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Identification of readouts for NAT10 inhibition in HGPS 
To investigate the impacts of NAT10 inhibition in vivo, and as the main cause of death 
in HGPS patients is due to heart dysfunction, we performed global gene-expression 
analyses on tissues derived from hearts of LmnaG609G/G609GNat10+/- and Remodelin 
treated LmnaG609G/G609G mice compared to their respective controls (Supplementary 
Data file 5). This work identified a specific set of genes (Supplementary Fig. 8a) – 
largely connected to metabolic pathways (Supplementary Fig. 8b) – as significantly up-
regulated (blue) or down-regulated (red) in LmnaG609G/G609G mice compared to WT 
(Supplementary Fig. 8a, lane 1). Interestingly, some of these gene-expression 
differences (* in Supplementary Fig. 8a) were counteracted by both Remodelin 
treatment (row 2) and Nat10 depletion (row 3), suggesting that these might comprise 
a gene-expression signature for amelioration of HGPS pathologies by NAT10 
inhibition. Collectively, these data highlighted a strong correlation between NAT10 
chemical inhibition or its genetic depletion on cellular imbalances caused by the 
LmnaG609G/G609G HGPS mutation. They also suggested the potential for gene-
expression signatures as biomarkers for HGPS and its alleviation. 
As acetylation of α-tubulin lysine 40 (K40) is a documented NAT10 target31,32, we 
evaluated it as a potential readout for NAT0 inhibition in vivo. Indeed, quantitative 
analyses established that patient-derived HGPS fibroblasts, as well as LmnaG609G/G609G 
mouse-derived skin cells and tissues, displayed increased acetyl-α-tubulin K40 when 
compared to WT controls (Fig. 5; Supplementary Fig. 9), probably associated with 
increased microtubule stability contributing to HGPS cellular phenotypes25. However, 
this was not associated with a significant and consistent increased NAT10 protein 
levels, suggesting that NAT10 enzymatic activity might be elevated, leading to 
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increased α-tubulin acetylation. In line with these findings, Remodelin treatment or 
reduced Nat10 gene dosage decreased acetyl-α-tubulin K40 levels in extracts from 
cells and mouse tissues (Fig. 5a, b; Supplementary Fig. 9a), in cultured cells (Fig. 5c), 
and as detected by in situ mouse-tissue staining (Fig. 5d; Supplementary Fig. 9b-d). 
These results thus indicated that α-tubulin K40 acetylation is increased in both human 
HGPS cells and in the mouse HGPS model in a manner counteracted by Remodelin 
treatment, thereby suggesting this acetylation mark as a potential disease biomarker 
and a readout for NAT10 inhibition in vivo. 
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Discussion 
HGPS, a debilitating premature aging disease whose features strikingly resemble 
accelerated aspects of normal aging, represents a paradigm for translational medicine 
in the arena of aging research 33. The complex nature of this segmental syndrome 
makes it difficult to target therapeutically, with standard therapeutic approaches mainly 
aiming at preventing the expression or the accumulation of progerin at the nuclear 
envelope. Thus, strategies that have so far received most attention largely involve 
targeting enzymes participating in the progerin pathway 10, including HMG-CoA 
reductase, farnesyl-pyrophosphate synthase, farnesyl transferase 21, 
isoprenylcysteine carboxyl methyltransferase, as well as modulating Lmna pre-mRNA 
splicing by morpholino compounds 24. Notably, there is encouraging evidence that 
HGPS children treated with the FTI lonafarnib display improved vascular stiffness and 
bone structure 21, as well as 33% increased survival based on Kaplan–Meier area 
under the curve estimations 10. Because FTI treatment is now essentially standard-of-
care and the HGPS patient population is small (~1 in 18 million) 34, further clinical trials 
will likely be arranged as combined therapies with lonafarnib 22.  
The results we have presented here show that NAT10 genetic depletion or its chemical 
inhibition by the compound Remodelin leads to healthspan and fitness improvements 
in both homozygous and heterozygous HGPS mice via a mechanism that appears to 
be independent of progerin. Reinforcing our conclusions, we have recently carried out 
further studies with a Remodelin derivative, Remodelin-fluor (Supplementary Fig. 10a), 
that in HGPS cells showed the same effect as Remodelin at half the Remodelin dose 
(Supplementary Fig. 10b). Using this compound in mice, we observed hair graying 
(Supplementary Fig. 10c) and no drug-induced weight loss (Supplementary Fig. 10d). 
Moreover, Remodelin-fluor treatment led to a significant decrease in the timeframe of 
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body weight loss with 30% increase in Kaplan–Meier area under the curve for treated 
mice as compared to vehicle treated mice (Supplementary Fig. 10e; Supplementary 
Table 3).  
While we did not see Remodelin-induced effects on low mineral density and bone 
mineral content in HGPS mice (see Supplementary Data file 3), we observed 
significant disease amelioration by Remodelin treatment and Nat10 genetic depletion 
in critical organs such as the heart. Notably, these cardiovascular effects were not only 
restricted to the aorta but also included impacts on other large vessels of the heart, 
such as the coronary arteries. These effects are of potential clinical relevance because 
advanced coronary disease is prevalent in HGPS patients, even in the absence of high 
blood pressure 29,35. We also note that, in contrast to FTI36, Remodelin decreases 
markers of genome instability in HGPS cells and organs. We showed in our previous 
work that combining FTI and Remodelin in HGPS patient cells does not improve the 
cellular phenotypes further compared to Remodelin alone (see Supplementary Fig. 8 
of Larrieu et al., Science 2014 – reference 25). However, as they act in different 
pathways, it is possible that the phenotypes in vivo would benefit from the drug 
combination, which will likely be the scope of ensuing studies. Collectively, our data 
thus highlight the potential for NAT10 inhibitors in treating HGPS in combination with 
lonafarnib, where additive therapeutic effects might be anticipated. 
While we found that complete Nat10 deletion resulted in early embryonic lethality in 
mice, Nat10 haploinsufficiency or chemical inhibition via Remodelin treatment did not 
confer any profound side effects. Because NAT10 is a 115 kDa protein with multiple 
functional domains, it could be that the lethality associated with its total loss is linked 
to an aspect of the NAT10 protein other than its N-acetyltransferase function. In this 
regard, we note that in Caenorhabditis elegans, a null allele of NAT10, nath-
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10(tm2624), causes fully penetrant embryonic lethality in the homozygous state. By 
contrast, the nath-10(N2) hypomorphic allele containing a polymorphism in the N-
acetyltransferase domain did not cause pathology in a homozygous setting, but instead 
conferred increased fitness and a strong competitive advantage over WT animals37. 
While these and our data are encouraging from the perspective of considering NAT10 
inhibition as a therapeutic approach for HGPS, the fact that our understanding of 
NAT10 biology is still in its infancy means that any clinical studies should be explored 
with caution. 
The small number of HGPS patients and the diverse nature of their pathologies provide 
challenges for the evaluation of potential new HGPS therapies in the clinic 22. If and 
when NAT10 inhibitors are explored in clinical settings, it will thus be extremely 
valuable to be able to assess target engagement. In this regard, we have identified 
gene-expression signatures that are associated with HGPS cells and which are 
rebalanced towards WT by either Remodelin treatment or NAT10 depletion. 
Furthermore, we have highlighted the potential for acetylated α-tubulin lysine 40 (K40), 
a known NAT10 target 31,32, as a biomarker for NAT10 inhibition in cells and in vivo. 
These findings also correlated with our previous data indicating that NAT10 inhibition 
ameliorates HGPS cellular phenotypes, at least in part by mediating microtubule 
destabilization 25. Since α-tubulin acetylation at K40 is elevated in HGPS tissues and 
cells compared to controls, it will be of interest to explore whether this biomarker could 
be used to monitor disease progression and also enhance our understanding of 
disease patho-biology. Finally, we note that because the hallmarks of HGPS are 
present at lower levels in the vasculature and other tissues of aged normal 
individuals33, NAT10 targeting might offer therapeutic opportunities in broader settings. 
In accord with such a possibility, we have recently reported effects of NAT10 inhibition 
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in normally aged smooth muscle cells 26, that support the potential for NAT10 inhibition 
in the context of normal ageing. 
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Methods 
Synthesis of Remodelin and derivatives  
All solvents and reagents were purified by using standard techniques or used as 
supplied from commercial sources (Sigma-Aldrich). NMR spectra were acquired on a 
Bruker 500 MHz instrument with deuterated solvents at 300 K. Notation for the 1H NMR 
spectral splitting patterns includes: singlet (s), doublet (d), triplet (t), broad (br) and 
multiplet/overlapping peaks (m). Signals are quoted as values in ppm and coupling 
constants (J) are quoted in Hertz. Mass spectra were recorded on a Micromass® Q-
Tof (ESI) spectrometer. The general procedure is highlighted in the Supplemental 
Material and Methods section. 
Animals 
 The care and use of all mice used to generate data for this protocol was carried out in 
accordance with UK Home Office regulations, UK Animals (Scientific Procedures) Act 
of 2013 under UK Home Office licenses which approved this which were reviewed 
regularly by the WTSI Animal Welfare and Ethical Review Board. Mice carrying the 
knockout-first conditional-ready allele Nat10tm1a(KOMP)Wtsi (abbreviated to Nat10tm1a) 
were generated on a C57BL/6N background as part of the Sanger Mouse Genetics 
Project (MGP). LmnaG609G (C57BL/6N) mice were imported from the laboratory of 
Carlos-Lopez Otin 24 and re-derived on the line C57BL/6NTac at the Wellcome Trust 
Sanger Institute (WTSI). Mice were euthanized by CO2 inhalation followed by cervical 
dislocation.  Mouse experimental procedures including oocyte culture and 
immunofluorescence, generation of oocytes and in-vitro fertilization, heart rate 
comparison, kyphosis index calculation, immunoblotting, immunofluorescence and 
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immunohistochemistry along other details on animal experimental methods are 
highlighted in the Supplemental Material and Methods section. 
Assessment of Remodelin toxicity in vivo and dosing 
Remodelin toxicity was assessed by Crown Biosciences on twelve 6 weeks old 
C57BL/6N female mice, with a body weight of 20g on average (animal supplier: 
Shanghai Laboratory Animal Center (SLAC, Shanghai, China): see Table S2. At WTSI, 
Remodelin and Remodelin Fluor were dissolved in a solution of 20% DMSO, 65% 
(45% 2-Hydroxypropyl-b-cyclodextrin solution, H5784 Sigma Aldrich) and 15% Tween 
80 (P8074 Sigma Aldrich). The “vehicle” treated animals were given this solution alone, 
without Remodelin. Remodelin and Remodelin Fluor were administered daily by oral 
gavage at 100mg per kg per day and 50mg per kg per day respectively (defined as 
non-toxic doses in toxicity studies), from day 21 and until culled. Additional details on 
animal experimental methods are highlighted in the Supplemental Material and 
Methods section. 
Cell lines  
Normal skin primary fibroblasts GM03440 and Hutchinson Gilford Progeria Syndrome 
(HGPS) skin primary fibroblasts AG11513 were purchased from Coriell Cell 
Repositories and used between passage number 9-17. Cells were grown in Dulbecco’s 
modified Eagle medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine 
serum (BioSera), 2mM L-glutamine, 100U per ml penicillin, 100 μg ml-1 streptomycin. 
All cell lines have been tested for mycoplasma contamination using Charles River 
Mycoplasma Testing Services. 
RNA extraction, qPCR analysis and RNAseq   
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RNA was extracted from tissues from n>5 independent mice per group using the 
RNeasy fibrous tissue mini kit (50) (cat. No.7404; Qiagen) and quantified using 
the NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific). 2µg RNA per 
sample was used to produce cDNA using the High-Capacity RNA-to-cDNA kit (cat. No. 
4387406; Applied Biosystems/Thermo Fisher Scientific). qPCR was carried out using 
the TaqMan system (Universal Master Mix II, with UNG, 4440038; Applied 
Biosystems/Thermo Fisher Scientific) on an Applied Biosystems Quant Studio 3 
machine. n≥3 mice were used for each genotype, with 50ng cDNA for each sample 
run in triplicate or quadruplicate. For RNAseq transcriptome data was obtained using 
paired end sequencing, with read lengths of 150 bp, on a NextSeq 500 machine. 
Trimmed reads were aligned using STAR aligner (version 2.4.2a) to the mouse 
genome assembly GRCm38. Additional details on RNA qPCR and RNAseq methods 
are highlighted in the Supplemental Material and Methods section. 
Antibodies  
Antibodies used in this study are: Lamin A/C (sc-6215 Santa-Cruz 1:200 for Western 
Blotting and 1:100 for Immunofluorescence), NAT10 (13365-1-AP ProteinTech Europe 
1:400 for Western Blotting), γH2AX (05-636 Millipore, 1:200 for Western Blotting and 
1:100 for Immunofluorescence), H2AX (ab11175 Abcam, 1:500 for Western Blotting), 
β Actin (ab8226, Abcam, 1:1000 for Western Blotting), Acetyl α Tubulin (K40) (5335 
Cell Signalling, 1:500 for Western Blotting and 1:100 for Immunofluorescence), α 
Tubulin (T9026 Sigma-Aldrich, 1:1000 for Western Blotting and 1:400 for 
Immunofluorescence), Nup98 (Abcam, ab50610 1:100 for Immunofluorescence) and 
tyrosinated-α-tubulin (YOL1/34, AbD Serotec, 1:200 for Immunofluorescence). 
Statistical analysis  
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For all analyses, the individual mouse was considered the experimental unit within the 
studies. Survival distributions of the different cohorts was plotted using the Kaplan–
Meier estimator and statistical analysis was performed using log-rank (Mantel-Cox) 
test. For survival analysis, we have completed power calculations for a large size effect 
and with an n of 10 per group. We could detect a 0% to 60% change in survival after 
treatment, 91% of the time (power of Fisher Exact test, 0.91). To meet the assumption 
of this statistical method, censoring of an individual mouse could only occur when the 
culling of a mouse was not related to the genotype/assessed-phenotype (e.g. fight 
wound leading to overt clinical presentation). Additional details on the high throughput 
phenotyping screens are highlighted in the Supplemental Material and Methods 
section. 
 
Data availability  
The mouse phenotypic data from the present manuscript are available in the 
supplementary Data files. Mouse phenotypic data will be available from IMPC 
(http://www.mousephenotype.org/). RNAseq data will be available from GEO public 
repository (https://www.ncbi.nlm.nih.gov/geo/). 
 
Supplementary Material  
Additional Material and Methods; Supplementary Figures 1 to 10; Supplementary 
Tables 1 to 4; Supplementary Data files 1 to 5; Supplementary Movies 1 to 3 
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Figure Legends 
Fig. 1: Oral administration of Remodelin enhances health of progeria mice. a, b: 
Cells were treated with vehicle or with 1µM Remodelin for 7 days. a Left: 
Representative immunofluorescence images of skin fibroblasts from LmnaG609G/G609G 
mice showing accumulation of the DNA double strand break marker γH2AX (green) 
and characteristic nuclear shape abnormalities observed by DAPI staining. All images 
were acquired with the same microscope intensity settings. Scale bar 20µm. Right: 
Quantification of γH2AX positive cells and cells with misshapen nuclei (>100 cells/n=3 
independent cell lines; mean ± s.d.; ns = not significant; *p<0.05, **p<0.01, ***p<0.001, 
two-tailed Student’s t-test). b Western blotting analysis of γH2AX levels (quantified in 
the right panel) in skin fibroblasts from the indicated genotypes. c and d 
Pharmacokinetic analyses of Remodelin in mice treated via oral (PO; n=3) or 
intravenous (IV; n=3) delivery; mean ± s.e.m. F: absolute bioavailability (%). e Tissues 
were collected after 2 weeks’ of daily PO administration of the indicated Remodelin 
concentration, and 1 hour after the last dosing. Remodelin was quantified by mass 
spectrometry in heart and skeletal muscle (n=3); mean ± s.e.m. f Survival based on 
20% body weight loss showing a 25% increase in Kaplan–Meier area under the curve 
in Remodelin treated LmnaG609G/G609G mice as compared to vehicle-treated mice (see 
Supplementary Table 3); (*Log-rank Mantel-Cox test; Chi-square 5.992). Due to 
animal welfare regulations, mice had to be sacrificed when they had lost 20% of their 
body weight compared to their individual weight maxima (end-point). However, at this 
defined end-point, Remodelin-treated mice displayed considerably better health 
compared to vehicle-treated controls (see supplementary movies and pathology 
assessments in Figure 2). 
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Fig. 2: Remodelin ameliorates cardiac and other pathologies of HGPS mice. 
Pathological staining in panels a-d was carried out on materials from endpoint mice 
(presented in Fig. 1e) of indicated genotypes (n=6 per genotype) treated with vehicle 
or Remodelin 100mg per kg per day (for detailed ages of the mice, see Supplementary 
Table 4). All images are representative (scale bar 50µm) and the correspondent bar 
graph quantifications are presented (mean ± s.e.m.; individual data points represented; 
ns = not significant; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 two-tailed Student’s 
t-test). In WT mice, Remodelin treatment has no significant effect as compared to 
vehicle treatment, and for simplicity these animals have been pooled in one group; the 
individual comparison is presented in Supplementary Fig. 2b. a Hematoxilin and eosin 
(H&E) staining of skin, indicating fat layer thickness (vertical bars indicate the fat layer) 
and showing amelioration of the fat layer thickness upon Remodelin treatment in 
HGPS mice. b H&E staining of heart aorta, indicating increased adventitial width in the 
HGPS mice as compared to WT controls, which is rescued by Remodelin treatment 
(arrowheads demarcate the aorta and vertical bars the adventitia). c DAPI staining of 
heart aorta, showing a decreased number of nuclei in the HGPS mice, rescued by 
Remodelin treatment (dotted white lines delineate the aorta edges). d Smooth muscle 
actin (SMA) staining (green) of heart aorta sections showing loss of integrity of the 
artery wall in HGPS mice, improved by Remodelin treatment (dotted white lines 
delineate the aorta). e and f Representative western blotting analysis of representative 
heart (e) and lung (f) tissues from endpoint mice, showing that Remodelin decreased 
γH2AX levels in LmnaG609G/G609G tissues (see quantification below each Western blot, 
relative to total H2AX levels). Western blots were performed more than once on 
n≥4/group.  
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Fig. 3: Engineering and characterization of a Nat10+/- mouse model. a Number of 
observed embryos (E14.5) and mice (21 days) compared to expected numbers 
(Mendelian frequencies) (*p<0.01; Chi-square analysis). b and c Nat10+/- mice display 
~50% reduction in Nat10 transcript level (b- each bar indicates individual mice ± SD of 
n=5 technical replicates/mouse) or protein expression in the indicated tissues (c- 
representative western blot; blots have been performed more than once on n≥3 mice) 
and quantification is presented on the right panel, relative to the Actin levels. d 
Heatmap of genes differentially expressed in the heart of Nat10+/- mice compared to 
wild-type from RNAseq analysis (n=2/genotype).  
 
Fig. 4: Genetic depletion of Nat10 enhances health of LmnaG609G mice. a 
LmnaG609G/G609GNat10+/- mice show 21% increased median age at endpoint compared 
to LmnaG609G/G609G (103 days versus 85 days respective median age at endpoint; 
based on mice being terminated upon reaching 20% body weight loss); (** Log-rank, 
Mantel-Cox test; Chi-square 32.61; also see Table S3). b-d Appearance (b) of back 
curvature (c) in LmnaG609G/G609G is delayed by Nat10 depletion as observed by images 
of terminal mice and X-rays from 9 week-old females, and quantified (kyphotic index) 
over time (d) (mean ± SEM; individual data points represented; mixed model analysis 
shows a significant difference between LmnaG609G/G609GNat10+/+ and 
LmnaG609G/G609GNat10+/- genotypes **p=0.01; raw data and extended conclusions and 
statistics are presented in Suppl. Data file 3). e Progressive heart function failure 
observed in LmnaG609G/G609G mice over time is delayed by Nat10 depletion, as 
observed by heart rate measurements at indicated times (mean ± SEM; individual data 
points represented; mixed model analysis shows a significant difference between 
LmnaG609G/G609GNat10+/+ and LmnaG609G/G609GNat10+/- genotypes ***p=0.004; raw data 
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and extended conclusions and statistics are presented in Data file S3). f RNA 
expression from heart tissues shows decreased p21 expression in 
LmnaG609G/G609GNat10+/- compared to controls (mean ± SEM; ns = not significant, 
*p<0.05 two-tailed Student’s t-test; individual data points represented). g 
Lmna+/G609GNat10+/- mice show 17% increased median age at endpoint compared to 
Lmna+/G609G (333 days versus 285 days respective median age at endpoint; based on 
mice being terminated upon reaching 20% body weight loss); (*Log-rank, Mantel-Cox 
test; Chi-square 4.98; also see Table S3) and more than 90 days between the longest 
lived Lmna+/G609GNat10+/- and the longest lived Lmna+/G609G mouse. 
 
Fig. 5: Identification of readouts for Nat10 inhibition in cells and tissues. a and b 
Representative images of western blots showing that 1µM Remodelin treatment for 7 
days decreases the high α-tubulin K40 acetylation in HGPS-patient derived cells (a) 
and mouse tissues (b). In panel (b), NAT10 chemical (lane 3) or genetic (lane 4) 
inhibition reverses high α-tubulin K40 acetylation levels in heart tissues from indicated 
mice; * indicates a cross-reacting band. We note that the ratio between Lamin A and 
C appears to vary between tissues. All western blotting experiments were performed 
at least three times independently (n≥3/genotype). c Representative 
immunofluorescence images of acetyl-α-tubulin K40 in HGPS-patient derived cells as 
compared to matching healthy fibroblasts. Scale bar 20µm. K40 α-tubulin acetylation 
(red) is increased in the HGPS-patient derived cells and decreased upon Remodelin 
treatment. d Representative immunofluorescence images (left) and quantification 
(right) of acetyl-α-tubulin K40 in aortas of terminal mice of the indicated genotypes and 
treatments. Scale bar 10µm. K40 α-tubulin acetylation (green; white arrowheads point 
to example of cells that show increased K40 acetylation) is increased in 
	 31 
LmnaG609G/G609G mice and significantly decreased in such mice upon Remodelin 
treatment (n=3; mean ± SD; individual data points represented; ns = not significant, 
*p<0.05; **p<0.01, ***p<0.001; two-tailed Student’s t-test). For better visualization, 
these are higher magnification snap-shots (red dotted squares) from images in 
Supplementary Fig. 9d. Quantification was performed on full size aorta images from 
n=3 independent mice.  
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Materials and Methods 
Synthesis of Remodelin and derivatives. All solvents and reagents were purified 
using standard techniques or used as supplied from commercial sources (Sigma-
Aldrich). NMR spectra were acquired on a Bruker 500 MHz instrument using 
deuterated solvents at 300 K. Notation for the 1H NMR spectral splitting patterns 
includes: singlet (s), doublet (d), triplet (t), broad (br) and multiplet/overlapping 
peaks (m). Signals are quoted as values in ppm and coupling constants (J) are 
quoted in Hertz. Mass spectra were recorded on a Micromass® Q-Tof (ESI) 
spectrometer. 
General procedure: The appropriate ketone or aldehyde was dissolved in 
isopropanol at a final concentration of 0.5 M and refluxed for 24h in the presence 
of an equimolar amount of thiosemicarbazide. The corresponding 
thiosemicarbazones were isolated by filtration and recrystallized from hot ethanol. 
Equimolar amounts of thiosemicarbazones and the desired haloketones were 
stirred at room temperature in isopropanol overnight at a final concentration of 0.2 
M. The resulting products were recrystallized from hot ethanol several times to 
yield pure products and were used without further purification. 
4-(4-cyanophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole ( Remodelin). 2-
cyclopentylidenehydrazine-1-carbothioamide (1 g, 4.46 mmol) and 2-bromo-4’-
cyanoacetophenone (700 mg, 4.45 mmol) were stirred overnight in 12 ml of 
isopropanol at room temperature. The precipitate was filtered and recrystallized 
from hot ethanol to yield the hydrobromide salt of the desired compound (559 mg, 
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1.98 mmol, 45%) as light yellow needles. 1H NMR (500 MHz, CDCl3): δ 12.11 (br 
s), 7.84 (d, J = 9.0 Hz, 2H), 7.81 (d, J = 9.0 Hz, 2H), 6.84 (s, 1H), 2.61 (t, J = 9.0 
Hz, 2H), 2.51 (t, J = 9.0 Hz, 2H), 1.94–1.80 (m, 4H); 13C NMR (125 MHz, CDCl3): 
δ 173.8, 169.5, 138.8, 133.5, 131.3, 126.3, 118.0, 114.1, 103.8, 33.7, 31.2, 25.2, 
25.0; HRMS (m/z): [M]+ calcd. for C15H15N4S, 283.1009; found, 283.1017. Molecule 
4 was resuspended in DMSO at 10mg/ml. 
4-(4-trifluoromethylphenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole 
(Remodelin Fluor). 2-cyclopentylidenehydrazine-1-carbothioamide (3.0 g, 18.7 
mmol) and 2-bromo-4’-(trifluoromethyl)acetophenone (5.0 g, 18.7 mmol) were 
stirred in isopropanol (150 mL) at r.t. for 24 h. The precipitate was filtered and 
recrystallized three times from hot ethanol to yield the hydrobromide salt of 
Remodelin Fluor as bright yellow needles (1.5 g, 3.7 mmol, 20%). 1H NMR (300 
MHz, CDCl3) δ 11.12 (br s, 2H), 7.80 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 
6.87 (s, 1H), 2.53 (t, J = 7.0 Hz, 2H), 2.47 (t, J = 7.0 Hz, 2H), 1.93–1.75 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ 171.9, 169.4, 140.3, 131.8 (q, J = 32.0 Hz), 131.6, 
126.5 (br q, J = 3.5 Hz, 2C), 126.1 (2C), 123.7 (q, J = 274.0 Hz), 103.5, 33.5, 30.6, 
25.1, 24.9. HRMS (m/z): [M+H]+ calculated for C15H15F3N3S, 326.0933; found, 
326.0950. See Fig. S2A for the synthesis reaction. 
Animals - ethical information 
Studies at Wellcome Trust Sanger Institute (WTSI). The care and use of all 
mice used to generate data for this protocol was carried out in accordance with UK 
Home Office regulations, UK Animals (Scientific Procedures) Act of 2013 under 
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UK Home Office licenses which approved this which were reviewed regularly by 
the WTSI Animal Welfare and Ethical Review Board.  
Studies at Crown Biosciences. The protocol and any amendment(s) or 
procedures involving the care and use of animals in this study were reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC) of 
CrownBio. During the study, the care and use of animals were conducted in 
accordance with the regulations of the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC AN-1308-017-66). 
Animals – experimental details 
Studies at WTSI. Engineering of the Nat10tm1a(KOMP)Wtsi (Nat10+/-) mice. Mice 
carrying the knockout-first conditional-ready allele Nat10tm1a(KOMP)Wtsi (abbreviated 
to Nat10tm1a) were generated on a C57BL/6N background as part of the Sanger 
Mouse Genetics Project (MGP). Detailed description of the Sanger Mouse 
Genetics Project methodology has been reported (Skarnes et al. 2011). Briefly, a 
promoter-containing cassette (L1L2_ Bact_P) was introduced upstream of the 
critical Nat10 exon 4 at position 103754720 of Chromosome 2, Build GRCm38. 
The vector containing Nat10tm1a was electroporated into C57BL/6N derived 
JM8A3.N1 ES cells. Correct ES cell gene targeting was confirmed by long-range 
PCR and quantitative PCR. Targeted ES cells were microinjected into blastocysts 
and used to generate chimeras. Germ-line transmission was confirmed by 
genotyping PCR analyses (http://www.knockoutmouse.org/kb/25/). Mice obtained 
from heterozygous intercross were genotyped for the Nat10tm1a allele by PCR. 
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LmnaG609G and LmnaG609G Nat10+/-mice. LmnaG609G (C57BL/6N) mice were 
imported from the laboratory of Carlos-Lopez Otin (1) and re-derived on the line 
C57BL/6NTac at the Wellcome Trust Sanger Institute (WTSI). Mouse genotyping 
was performed from tail biopsies using a protocol already described (1). Nat10 KO 
mice were generated in the C57BL/6NTac background as part of the Mouse 
Genetics Project at the WTSI (2). The double mutant combinations were 
maintained on the same C57BL/6NTac background. Experimental animals were 
maintained under close supervision following the following protocol. Upon weaning 
LmnaG609G/G609G homozygous animals and littermate Lmna+/+ wild-type (WT) 
controls were set up in experimental cohorts and weighed weekly. WT and mutant 
experimental animals were housed together randomly in multiple cages to reduce 
cage bias. Treatment and weight measurements were carried out by the mouse 
facility technicians blinded of the scientific background or goals of the experiment. 
When animals would reach 10% body weight (BW) loss they would be weighed 
every other day and wet pellets provided on the floor daily. Upon 15% BW loss 
animals would be weighed and monitored daily and culled when they passed over 
19% BW loss. A number of male mice of the LmnaG609G/G609G genotype have 
presented with penile prolapse and upon detection they have been culled and 
indicated as incidence of penile prolapse (Figure 3B). Over the course of the study 
3 mice of the LmnaG609G/G609G genotype have been found dead. No drug or naïve 
test was performed prior to treatment or testing. Animals have been euthanized by 
CO2 inhalation followed by cervical dislocation. WTSI facility runs periodic health 
reports that indicate that the mice were free of known viral, bacterial and parasitic 
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pathogens. For analysis of embryonic development of Nat10 KO mice, timed 
matings were performed at noon and the day of vaginal plug detection was defined 
as embryonic day E0.5. Movies and pictures were made using a Sony Cyber-shot 
DSC-HX10V GPS camera. Mouse health evaluation was performed by trained 
technicians using established protocols (3).  
Studies at Crown Biosciences. For testing drug bioavailability pilot studies have 
been performed on 7 weeks old C57BL/6 mice, weighing between 18.8-19.9g. The 
mice were ordered from Shanghai Laboratory Animal Center (SLAC, Shanghai, 
China). Animals have been euthanized by CO2 inhalation followed by cervical 
dislocation. 
Animals – housing and husbandry 
Studies at WTSI. Our mice are maintained in a specific pathogen-free unit on a 
12-h light: 12-h dark cycle with lights off at 19:30 and no twilight period. The 
ambient temperature is 21 ± 2 °C, and the humidity is 55 ± 10%. Mice are housed 
using a stocking density of 3–5 mice per cage (overall dimensions of caging: 365 
× 207 × 140 mm (length × width × height), floor area 530 cm2) in individually 
ventilated caging (Tecniplast, Sealsafe 1284L) receiving 60 air changes per hour. 
In addition to Aspen bedding substrate, standard environmental enrichment of two 
Nestlets, a cardboard fun tunnel and three wooden chew blocks are provided. Mice 
were given water and diet (Teklad Global 18% Protein Rodent Diet/Envigo) ad 
libitum.  
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Studies at Crown Biosciences. Mice were housed at an average temperature of 
23.5ºC with a 7:00 am - 19:00 pm light and 19:00 pm – 7:00 am (next day) darkness 
cycle in polysulfone IVC cages (3 mice/cage; 325 mm x 210 mm x 180 mm). Mice 
were fed Co60 irradiation sterilized dry granule mouse diet. Animals had free 
access to food and water during the entire study period. Mice had no drug or test 
naïve prior to treatment. 
Small molecule dosing. Remodelin and Remodelin Fluor were dissolved in a 
solution of 20% DMSO, 65% (45% 2-Hydroxypropyl-b-cyclodextrin solution, H5784 
Sigma Aldrich) and 15% Tween 80 (P8074 Sigma Aldrich). The “vehicle” treated 
animals were given this solution alone, without Remodelin. Remodelin and 
Remodelin Fluor were administered daily by oral gavage at 100mg/kg/day and 
50mg/kg/day respectively (defined as non-toxic doses in toxicity studies), from day 
21 and until culled. Dosing needle - Instech FTP-20-30 Plastic feeding tubes, 20ga 
X 30mm 1 ml syringes and 20ga dosing needles were used as they are appropriate 
for the volume to be administered and for the size of the mice. During each dosing 
session, the vehicle only was administered to each animal in the control group 
before administering Remodelin to each animal in the treated group to avoid cross-
contamination. Body weights were recorded for each mouse before dosing and the 
dose volume was calculated according to the body weight. The mice were 
restrained by scruffing the back of the neck, the dosing needle was presented 
through the mouth down into the oesophagus in a smooth motion. Once in situ, the 
dose (calculated to a 100 to 200µl volume) was administered to the mouse. 
Additional food was moistened and added to the floor of each cage to facilitate 
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food consumption following the dosing procedure. The end-point criteria were 
represented by 20% body weight loss, mice that were found death or moribund 
and mice that presented with penile prolapse, a distinctive clinical phenotype for 
the progeric male mice. All animals were used to represent the survival curves; 
n=1 Remodelin treated LmnaG609G/G609G mouse presented with hemangioma at 79 
days of age and was censored into the survival analysis. Treatment and weight 
measurements were carried out by the mouse facility technicians blinded of the 
scientific background or goals of the experiment. The comparison between 
LmnaG609G/G609G vehicle and LmnaG609G/G609G no treatment showed no significant 
difference (p=0.56). We utilized an informally method of randomizing within each 
batch to assign mice to treatment using mouse database ID. Mice were used from 
multiple cages and litters. 
Assessment of Remodelin toxicity in vivo. Remodelin toxicity was assessed by 
Crown Biosciences on twelve 6 weeks old C57BL/6N female mice, with a body 
weight of 20g on average (animal supplier: Shanghai Laboratory Animal Center 
(SLAC, Shanghai, China): see Table S2. 
LC/MS/MS method was used to assess Remodelin concentration in plasma. 
Minimum of 6 standards with lowest limit of quantification (LLOQ) <3 ng/mL and 
minimum of 5 standards back were calculated to within ±20% of their nominal 
concentrations. Total 6 quality control (QC) samples at 3 concentrations (Low, Mid 
and High) were included in sample runs with a minimum of 4 QC back calculated 
to within ±20% of their nominal concentrations. 
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Pharmacokinetics Evaluation of Remodelin in ICR Mouse via IV and PO 
administration. The pharmacokinetics of Remodelin was assessed by Crown 
Bioscience. The administration of Remodelin and sample collection in each study 
group are shown in the following experimental design table (IV= intravenous; P.O.= 
per os (by mouth)). Animals were randomly assigned to groups: see Table S3. 
Before grouping and treatment, all animals were weighed, and assigned into 
groups using randomized block based on their body weight. Within each block, 
experimental animals were randomly assigned to the different groups. 
Randomized block design was used to assign experimental animals to ensure that 
each animal has the same probability of being assigned to any given treatment 
groups and therefore minimise systematic error. Animals showing obvious signs of 
severe distress and/or pain were humanely sacrificed. In case of following 
situations, the animals were euthanized: Animal has lost significant body mass 
(>20%, emaciated). The animals found to be having other severe health problems, 
i.e., prolonged diarrhea, persistent anorexia, lethargy or failure to respond to gentle 
stimuli, labored respiration, or that cannot get to adequate food or water, etc., were 
removed from the study and sacrificed (n=3; sub-cutaneous administration; data 
not shown). LC/MS/MS method development was used to assess test compound 
in plasma. Minimum of 6 standards with LLOQ <3 ng/mL and minimum of 5 
standards back were calculated to within ±20% of their nominal concentrations. 
Total 6 QC samples at 3 concentrations (Low, Mid and High) will be included in 
sample runs with a minimum of 4 QC back were calculated to within ±20% of their 
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nominal concentrations. Plasma samples were analysed following the above 
criteria. 
Immunoblotting. Mice were euthanized by CO2 inhalation followed by cervical 
dislocation.  Mouse tissues were snap-frozen in liquid N2 and immediately stored 
at -80ºC. 40µl/g of protein extraction buffer (50 mM Tris pH 7.5, 150 mM NaCl, 
0.1% NP-40, 0.5% CHAPS, 5 mM MgCl2, 10% glycerol, MilliQ distilled water) or 
Laemmli Buffer (S3401 SIGMA). Mini-protease and mini-phosphatase tablet was 
added to each sample in conjunction with a stainless-steel bead (7mm; QUIAGEN) 
and physical disrupted using the TissueLyser LT (QIAGEN), in 2x5 min cycles with 
5 min rest on ice in between. After removing the stainless-steel bead, the lysates 
were sonicated using the BioruptorTM Next Gen (Diagenode), 2x20 min cycles (30 
sec on, 30 sec off), and a 20 min rest period on ice in between. The tissue derbies 
were separated from the protein content by centrifugation using a bench Eppendorf 
centrifuge 5417R (Eppendorf) for 30 min, at 4ºC and 16400 rpm. The quantity of 
protein was measured using PierceTM BCA protein assay kit (Thermo Scientific) 
and Muiltyskan GO (Thermo Scientific) at an absorbance of 562 nm. Before 
loading, lysates were diluted with a solution of 0.01% bromophenol blue and 200 
mM DTT and boiled for 5 min at 95°C. Proteins from individual mice/cell lines were 
resolved by SDS-PAGE on 4-12% gradient gels (NUPAGE, Life Sciences) and 
transferred onto nitrocellulose membrane (Protran; Whatman). Secondary 
antibodies conjugated to IRDye 800CW were from LI-COR Biosciences. Western 
blotting shown are representative of 3 repeats. Detection and quantification was 
performed with an imager (Odyssey; LI-COR Biosciences). 
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Cell lines. Normal skin primary fibroblasts GM03440 and Hutchinson Gilford 
Progeria Syndrome (HGPS) skin primary fibroblasts AG11513 were purchased 
from Coriell Cell Repositories and used between passage number 9-17. Cells were 
grown in Dulbecco’s modified Eagle medium (DMEM, Sigma-Aldrich) 
supplemented with 10% fetal bovine serum (BioSera), 2mM L-glutamine, 100U per 
ml penicillin, 100 μg ml-1 streptomycin. All cell lines have been tested for 
mycoplasma contamination using Charles River Mycoplasma Testing Services. 
Immunofluorescence. Isolation and culture of adult mouse fibroblasts from skin 
and lungs was performed using an established protocol, as previously described 
(4). Cells were washed with PBS and fixed for 10 min with 4% PFA in PBS. Cells 
were permeabilised for 5 min with PBS/0.2% Triton X-100, and blocked with 
PBS/0.2% Tween 20 (PBS-T) containing 5% BSA. Coverslips were incubated for 
1 h with primary antibodies and for 30 min with appropriate secondary antibodies 
coupled to Alexa Fluor 488 or 594 fluorophores (Life Technologies), before being 
incubated with 2μg/ml DAPI. Pictures were acquired with a FluoView 1000 
confocal microscope (Olympus) and images were quantified using ImageJ. All the 
immunofluorescence experiments were performed at least 3 times independently 
and the pictures shown in the figures are representative images of the at least 3 
experiments. 
Histology and immunohistochemistry. All major organs were isolated following 
euthanasia and then fixed in 10% formalin overnight. The second day the fixed 
organs were transferred to 70% ethanol, were placed in cassettes, embedded in 
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paraffin and serial 5 μm sections were collected on Superfrost Plus slides (Fisher) 
using a Leica microdissection system (LMD7000). Hematoxilin and eosin (HE) and 
immunohistochemistry staining were performed as previously described (5). The 
organs were examined for abnormalities by a Board Certified Veterinary 
Pathologist (MJ). Sections of heart containing aortic outflow, pulmonary artery and 
myocardium were stained using a primary antibody against alpha smooth muscle 
actin (SMA-Sigma Aldrich Cat No: A2547 1:1000) and secondary antibody (Alexa 
488 Life Technologies at 1:100). The heart sections were also stained using DAPI 
alone and with an antibody against Acetyl α Tubulin (K40) (5335 Cell Signalling). 
Representative histology images were obtained from whole slide images scanned 
on a Hamamatsu NanoZoomer in brightfield and fluorescence modes. The 
thickness of the subcutaneous fat layer in the skin and nuclei number in the aorta 
were measured using whole slide images and the Hamamatsu NDP view software 
at a magnification of ×200 (resolution of 0.45μm per pixel). The skin (always the 
same region/the flanks) and aorta regions for analysis were identified by a 
pathologist (MJ) and manually annotated using the HALO image analysis software 
(Indica Labs). The cells inside these annotated regions were identified and counted 
using the HALO software CytoNuclear v1.5 algorithm, the output of cell density 
(cells/mm2) was used to differentiate between the treatment groups. SMA intensity 
quantification was performed using ImageJ.  
Oocyte culture and immunofluorescence. Oocytes were isolated from ovaries 
of 8-week old C57BL/6N female mice and cultured in M2 medium covered by 
mineral oil at 37ºC. Isolated oocytes were maintained in prophase arrest by 
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addition of 250 µM dbcAMP (Sigma; D0627). To induce resumption of meiosis, 
oocytes were released into dbcAMP-free medium. For immunofluorescence, 
oocytes were fixed for 30 min at 37ºC in 100 mM HEPES (pH 7; titrated with KOH), 
50 mM EGTA (pH 7; titrated with KOH), 2% formaldehyde (methanol free) and 
0.2% Triton X-100. Fixed oocytes were incubated in PBS with 0.1% Triton X-100 
overnight at 4ºC. Antibody incubations were performed in PBS, 3% BSA and 0.1% 
Triton X-100. Primary antibodies used were rat anti-Nup98 (Abcam, ab50610; 
1:100) and rat anti-tyrosinated-α-tubulin (YOL1/34, AbD Serotec; 1:3000). 
Secondary antibodies used were Alexa-Fluor-488-labelled anti-rat (Molecular 
Probes; 1:400). DNA was stained with 5 mg ml-1 Hoechst 33342 (Molecular 
Probes). Images were acquired with a Zeiss LSM710 microscope equipped with a 
63x C-Apochromat 1.2 NA water-immersion objective. 
Generation of oocytes and in-vitro fertilization. Three 4 to 5 week old 
C57BL/6NTac females per sperm sample were super-ovulated by intraperitoneal 
(IP) injection of 5IU of pregnant mare’s serum at 17:00 hrs (on a 12hr light/dark 
cycle, on at 07:00/off at 19:00) followed 48hrs later by an IP injection of 5IU human 
chorionic gonadotrophin. Oviducts were dissected at approximately 07:50am on 
the day of the in-vitro fertilization (IVF), and cumulus-oocyte complexes were 
transferred into the IVF fertilization dish containing human tubal fluid (HTF)+ 
glutathione (GSH). An aliquot of 20µl of sperm from the pre-incubation dish was 
then added to the fertilization dish. After allowing 3-4 hours for fertilization to occur 
the embryos were washed and cultured overnight in HTF at 37oC, 5% CO2 in air. 
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Antibodies. Antibodies used in this study are: Lamin A/C (sc-6215 Santa-Cruz), 
NAT10 (13365-1-AP ProteinTech Europe), γH2AX (05-636 Millipore), H2AX 
(ab11175 Abcam), β Actin (ab8226, Abcam), Acetyl α Tubulin (K40) (5335 Cell 
Signalling), α Tubulin (T9026 Sigma-Aldrich), Nup98 (Abcam, ab50610) and 
tyrosinated-α-tubulin (YOL1/34, AbD Serotec). 
High throughput phenotyping screen. The high-throughput phenotyping, is 
based on a pipeline concept where a mouse is characterized by a series of 
standardized and validated set of tests underpinned by standard operating 
procedures. The phenotyping tests chosen cover a variety of disease-related and 
biological systems, including the metabolic, cardiovascular, bone, neurological and 
behavioral, sensory and hematological systems and clinical chemistry. The data 
were obtained as detailed previously (2) following the standard operating 
procedures at IMPReSS (www.mousephenotype.org/impress). Factors thought to 
affect the variables were standardized as far as possible. Where standardization 
was not possible, steps were taken to reduce potential bias. For example, at WTSI 
the impact of different people completing the experiment was minimized 
(“minimized operator”) as defined in the  Mouse Experimental Design Ontology 
(MEDO) (6) as “The process by which steps are taken to minimize the potential 
differences in the effector by training and monitoring of operator.” 
(http://bioportal.bioontology.org/ontologies/MEDO/?p=summary). The data 
captured with the MEDO ontology can be accessed at 
http://www.mousephenotype.org/about-impc/arrive-guidelines. Pre-set reasons 
are established for QC failures (e.g. insufficient sample) and detailed within 
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IMPRESS (www.mousephenotype.org/impress) providing standardized options as 
agreed by area experts as to when data can be discarded. Data can only be QC 
failed from the dataset if clear technical reasons can be found for a measurement 
being an outlier. Reasons are provided and this is tracked within the database.   
Phenotyping data are collected at regular intervals on age-matched wildtype 
(control) mice of equivalent genetic backgrounds. Cohorts of at least seven 
homozygote mice of each sex per knockout line were generated. If no 
homozygotes were obtained from 28 or more offspring of heterozygote 
intercrosses, the line was deemed homozygous lethal. Similarly, if less than 13% 
of the pups resulting from intercrossing were homozygous, the line was judged as 
being homozygous sub-viable. In such circumstances, heterozygote mice were 
committed to the phenotyping pipelines. 
 The random allocation of mice to experimental group (wildtype versus knockout) 
was driven by Mendelian Inheritance. Reflecting the high-throughput nature of the 
phenotyping pipeline, blinding to the identity of knockout lines during phenotyping 
was not employed as the cage cards include genotype information, though with a 
high throughput environment without a defined hypothesis, the potential bias is 
minimized.  The individual mouse was considered the experimental unit within the 
studies. Further detailed experimental design information (e.g. exact definition of 
a control animal) is captured by with a standardized ontology as detailed in Karp 
et al (6) and is available from the IMPC portal 
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(http://www.mousephenotype.org/about-impc/arrive-guidelines). For each line, 
n≥5 mice/genotype were studied.  
Comparison between Wild-type, LmnaG609G/G609G, and LmnaG609G/G609GNat10+/-
. Mutant mice at 9 or 12 weeks of age were analyzed in separate groups (n≥3 for 
each sex/genotype). Prior to entering this workflow, due to the progeria phenotype, 
mice were assessed for adverse health and welfare to ensure that mice were in a 
suitable condition for analysis. No mice were excluded from study on this basis.  
Mice were anaesthetized with 110mg/kg body weight ketamine and 11mg/kg body 
weight xylazine given intraperitoneally. Mice were then imaged sequentially with 
three modalities, high resolution X-Ray imaging (MX-20, Faxitron, Tucson, AZ), 
Dual-energy X-ray Absorptiometry for body composition (Piximus II, GE 
Healthcare, Hatfield, UK) and with light photography for imaging of dysmorphology.  
A whole-body lateral image using the MX-20 was collected for the analysis of spinal 
curvature by trained persons using a standard defined position to minimize 
inconsistencies between mice. Following this and still while under anaesthesia, 
blood collection was performed to obtain samples for plasma chemistry and 
haematological analysis via the retro-orbital route using capillary tubes (cat. no. 
078042; Scientific Laboratory Supplies). Mice were then culled by cervical 
dislocation and heart removal, followed by removal of other organs for analysis.  
During this series of procedures, the experimenters collecting images and blood 
samples were not blinded from the genotypes of the mice. However, the analysis 
of the blood parameters was blinded and uploaded onto a database. The kyphosis 
index (KY) was calculated as the ratio between a line drawn between the caudal 
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margin of the last cervical vertebra to the caudal margin of the sixth lumbar 
vertebra and a line perpendicular to this from the dorsal edge of the vertebra at the 
point of greatest curvature as previously described (7). For the data collected on 
the back curvature, a multilevel regression model was performed using R 
(package:nlme version 3.1). A model (Eq. 1), treating genotype, sex and age as 
fixed effects whilst the repeat measure nature of the dataset was accounted for by 
treating mouse as a random effect, was fitted to the data. The genotype effect was 
tested and contrasts used to directly compare LmnaG609G/G609G and 
LmnaG609G/G609GNat10+/- mice if the genotype effect was significant. For the 
hypothesis test of primary interest, the impact of genotype, p-values were adjusted 
to account for the multiple comparisons completed to control the false discovery 
rate to 0.05. Visual inspection of the data was used to assess whether variance 
was equal and no outliers were present thus ensuring the assumptions of the 
model were met. 
Y ~ Genotype + Sex + Age + (1|Mouse) [Eq. 1] 
For the survival analysis, the end-point criteria were represented by 20% body 
weight loss, mice that were found death or moribund and mice that presented with 
penile prolapse, a distinctive clinical phenotype for the progeric male mice. All 
animals were used to represent the survival curves; one LmnaG609G/G609GNat10+/- 
was reported by the technician staff with a swollen abdomen at 32 days of age and 
requested to be culled. The mouse was active and within the weight range for the 
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age. No abnormality was found at necropsy but because it was culled for other 
reasons than end-point criteria it was censored from the analysis. 
Statistical analysis. For all analyses, the individual mouse was considered the 
experimental unit within the studies. Survival distributions of the different cohorts 
was plotted using the Kaplan–Meier estimator and statistical analysis was 
performed using log-rank (Mantel-Cox) test. For survival analysis we have 
completed power calculations for a large size effect and with an n of 10/group. We 
could detect a 0% to 60% change in survival after treatment, 91% of the time 
(power of Fisher Exact test, 0.91). To meet the assumption of this statistical 
method, censoring of an individual mouse could only occur when the culling of a 
mouse was not related to the genotype/assessed-phenotype (e.g. fight wound 
leading to overt clinical presentation).  
Nat10+/- and LmnaG609G high-throughput phenotyping data. Knockout data 
collected across multiple batches were compared to a year’s worth of control data 
collected on mice from the same genetic background.  For the continuous data, an 
iterative top down mixed modelling strategy fitting equation 1 was performed as 
described (8) using PhenStat, an R package version 2.6.0 (9) freely available from 
Bioconductor (10) The package’s mixed model framework was used as default 
except the argument equationType was set to withoutWeight and 
dataPointsThreshold was set to 2. The model optimisation implemented will adjust 
for unequal variances. The genotype contribution test p value was adjusted for 
multiple testing to control the false discovery rate to 5%. This statistical method 
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has been studied through simulations and resampling studies (11) and found to be 
robust and reliable with a multi-batch workflow, where the knockout mice are split 
into multiple phenotyping batches.  
 
Y~ Genotype + Sex + Genotype*Sex + (1|Batch) [Eq. 2] 
 
For the categorical data, a Fisher Exact Test was fitted comparing the proportions 
seen between wildtype and knockout mice for each sex independently using 
PhenStat FE Framework with the default settings. This simple method is 
appropriate for categorical phenotyping data as discussed in Karp et al. 2012 (8). 
The minimum p value returned from the two tests for a variable was adjusted for 
multiple testing to control the false discovery rate to 5%. The number of caudal 
vertebrae were recoded to a categorical variable by classifying mice with less than 
28 vertebrae as “low”, those with greater than 29 as “high” and all others as 
“normal”. For ABR data, the knockout dataset was smaller with only four data 
points for each variable, therefore to meet the assumption of the test, the data was 
analysed using a reference range plus methodology (9) which calls a significant 
phenotype when the majority of animals lie outside the natural variation seen in 
the control animals. The implementation within PhenStat RR framework is based 
on classifying the analysable variable values as high, normal, low based on the 
natural variation seen within the control data and comparing the proportions seen 
with a Fisher Exact Test. The minimum p value returned from the two tests (1: 
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increase in high classification and 2: increase in low classification) for a variable 
was adjusted for multiple testing to control the false discovery rate to 5%. 
As a high throughput program with many variables and multiple analysis tools, a 
single power calculation would not help; instead, the pipeline has been developed 
through empirically selecting a workflow which has historically given hits at a rate 
that would be cost effective for the program.  
Comparison between Wild-type, LmnaG609G/G609G, and LmnaG609G/G609GNat10+/- 
Mixed model data analysis was performed using R (package: nlme version 3.1). 
An iterative top down modelling strategy was implemented starting with the fully 
loaded model (Eq. 2). For the Origins of Bone and Cartilage Disease (OBCD) 
screen (12), where only one sex was collected, Eq. 3 details the starting model. 
The final model was selected by first selecting a structure for the random effects, 
then a covariance structure for the residual, and then the model reduced by 
removing non-significant fixed effects. Then the genotype effect was tested, model 
diagnostics assessed and contrasts used to directly compare LmnaG609G/G609G and 
LmnaG609G/G609GNat10+/- mice if the genotype effect was significant. During the 
model building stage, the hypotheses were tested with a threshold of p<0.05. For 
the hypothesis test of primary interest, the impact of genotype, p-values were 
adjusted to account for the multiple comparisons completed to control the false 
discovery rate to 0.05. The difficulty associated with the breeding and viability 
challenged the production of these mice for the array of phenotyping used in this 
paper. 136 mating pairs were set up over more than 3 years that generated 181 
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LmnaG609G homozygous (single or Nat10 double-mutant) mice that were used at 
specific ages together with littermate controls. The n was thus limited by breeding 
constraint and we have used n>5.  
Y=Genotype + Age + (1|Batch)  [Eq. 3] 
Heart rate comparison. Heart measurements were performed using the 
ecgTUNNEL (emka TECHNOLOGIES), a noninvasive ECG system, using the 
manufacturer recommendations as previously described (13). All ECG recording 
sessions were performed during daytime and the data analyzed using the iox2, 
data acquisition and analysis software (emka TECHNOLOGIES). For data 
acquisition, a series of repeated measurements were done on the same animal at 
each time-point and data for the same animal was collected over the different week 
intervals. For the data collected on the heart rate screen, a multilevel regression 
model was performed using R (package:nlme version 3.1). A model [Eq. 1], 
treating genotype, sex and age as fixed effects whilst the repeat measure nature 
of the dataset was accounted for by treating mouse as a random effect, was fitted 
to the data. The genotype effect was tested and contrasts used to directly compare 
LmnaG609G/G609G and LmnaG609G/G609GNat10+/- mice if the genotype effect was 
significant. For the hypothesis test of primary interest, the impact of genotype, p-
values were adjusted to account for the multiple comparisons completed to control 
the false discovery rate to 0.05. Visual inspection of the data was used to assess 
whether variance was equal and no outliers were present thus ensuring the 
assumptions of the model were met. 
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RNA extraction and qPCR analysis. RNA was extracted from tissues from n>5 
independent mice/group using the RNeasy fibrous tissue mini kit (50) (cat. 
No.7404; Qiagen) and quantified using the NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific). 2µg RNA/sample was used to produce cDNA using the 
High-Capacity RNA-to-cDNA kit (cat. No. 4387406; Applied Biosystems/Thermo 
Fisher Scientific). qPCR was carried out using the TaqMan system (Universal 
Master Mix II, with UNG, 4440038; Applied Biosystems/Thermo Fisher Scientific) 
on an Applied Biosystems Quant Studio 3 machine. n≥3 mice were used for each 
genotype, with 50ng cDNA for each sample run in triplicate or quadruplicate. 
Thermo Fisher Scientific Nat10 (Mm00462302_m1) and Cdkn1a/p21 
(Mm00432448_m1) primers were used as experimental probes while Gapdh 
(Mm99999915_g1), Actb (Mm00607939_s1) and/or Rn18s (Mm03928990_g1) 
were used as endogenous controls. The Relative Standard Curve pre-set 
programme was used throughout and data analysis was performed using the 
Relative Quantification application, powered by the Thermo Fisher Scientific cloud 
platform. To account for technical replicates the mean value for a mouse was 
calculated and used for the statistical assessment. For each sample, data was 
normalized to the endogenous controls and represented as relative to the wildtype 
control. Data was evaluated by visual inspection and an F test of the variance was 
calculated in order to estimate normality and equal variance. 
All graphs and part of the statistical analysis in the manuscript (Student’s t-tests; 
Kaplan–Meier estimator and statistical analysis; Fishers exact test) were 
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generated and calculated using GraphPad Prism version 7.0a for Mac OS X, 
GraphPad Software, La Jolla California USA, www.graphpad.com. 
RNAseq data analysis. RNA was extracted as described above and quality 
control assessed using the 2100 Bioanalyzer (Agilent Technologies). Because of 
financial constrains we used n=2 mice/group. Transcriptome data was obtained 
using paired end sequencing, with read lengths of 150 bp, on a NextSeq 500 
machine. Trimmed reads were aligned using STAR aligner (version 2.4.2a) to the 
mouse genome assembly GRCm38. Normalisation of the read counts and 
differential expression analysis was performed using three commonly used 
software programmes: DeSeq2 (14), edgeR (15) and Cuffdiff 2 (16). Our 
conservative approach defined genes differentially expressed as those found to be 
in common between the results of at least two of the three software programmes 
mentioned above. The log-2 fold change in gene expression presented in Figure 
2d and Figure 4e correspond to the log-2 fold change returned by DeSeq2. 
DeSeq2 and edgeR used as an input raw read counts produced by featureCounts 
from the Bioconductor (version 3.3) Rsubread package (14) in R version 3.3.1. For 
the DeSeq2 and edgeR analyses, we filtered out genes that had 0 or 1 read 
support across all samples. In the DeSeq2 differential expression analysis, we 
selected genes that were up or down regulated at a FDR lower than 0.1. In edgeR 
differential expression analysis, we selected genes up or down regulated with a p-
value less than 0.05.  
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Gene ontology analysis was performed using the mouse genome informatics 
(MGI) visual annotation display (VLAD) (17). For the analysis of the biological term 
fold enrichment, a ratio between the frequency of genes in our set to frequency of 
genes in the whole genome was calculated (18). 
Data availability. The mouse phenotypic data from the present manuscript are 
available in the supplementary Data files. Mouse phenotypic data will be 
available from IMPC (http://www.mousephenotype.org/). RNAseq data will be 
available from GEO public repository (https://www.ncbi.nlm.nih.gov/geo/). 
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Supplementary figures 
Fig. S1: Assessment of Remodelin effect in vivo. a Toxicity assessment of 
Remodelin treatment on 6-week old C57BL/6N female mice. Group 1 (n=3) and 2 
(n=3) were administered daily oral doses of the molecule (PO) as indicated, 
whereas group 3 (n=3) received Remodelin by subcutaneous injection (SC). No 
body weight loss or toxicity was observed on these regimes after 2 weeks of 
treatment. Error bars represent mean ± SD. b Long-term treatment of the 
LmnaG609G/G609G mice with Remodelin (100mg/kg/day) showed no drug-dependent 
body weight loss. Error bars represent mean ± SD. c The only observed side effect 
of Remodelin treatment (in all mice) was hair greying, appearing after several 
weeks’ treatment in both WT (left mouse on each panel) and LmnaG609G/G609G mice 
(right mouse).  
Fig. S2: Identification of a more potent Remodelin analogue. a Synthesis and 
chemical structure of Remodelin-fluor (left) and its analogue Remodelin (right). b 
Representative images of U2OS cells transfected with siRNA control (siCT) or 
siRNA against Lamin A/C (siLMNA). Nuclear shape was assessed by microscopy 
following DAPI staining of the nucleus. Remodelin-fluor showed increased potency 
in rescuing nuclear shape defects of Lamin A/C depleted cells (siLMNA) compared 
to Remodelin, and relative to the mock-treated cells (NT). c Representative images 
of mice treated with Remodelin-fluor. Long-term treatment of Remodelin-fluor at 
50mg/kg/day only caused mild hair greying, specifically around the eyes, in all 
treated mice. d No drug dependent body weight loss or toxicity was observed on 
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50mg/kg/day of Remodelin-fluor treatment. Bars represent mean ± SD. e 
50mg/kg/day oral Remodelin-fluor delivery led to a 30% Kaplan–Meier area under 
the curve lifespan increase in the LmnaG609G/G609G mice (see Table S1). Data for 
the vehicle-treated LmnaG609G/G609G mice (red line) was combined across 
experiments to allow comparison of survival and is also presented in Fig. 1e. 
****Log-rank (Mantel-Cox) test comparison between LmnaG609G/G609G treated with 
Vehicle and LmnaG609G/G609G treated with Remodelin-fluor. 
Fig. S3: Remodelin improves the coronary pathology of HGPS mice. a 
Representative images of hematoxilin and eosin (H&E) and smooth muscle actin 
(SMA) staining of heart sections representing coronary arteries (left panels; size 
bar 100µm) showing improved integrity of the artery wall in terminal 
LmnaG609G/G609G mice treated with Remodelin. Right panel: bar graph of the 
quantification of the SMA mean intensity/15µm2 (mean ± SD; individual data points 
represented; ns = not significant; **p<0.01, ***p<0.001; two-tailed Student’s t-
test;). b Bar graph presenting the quantification of different indicated parameters 
in the aorta of the wild type (WT) Remodelin treated mice (n=3) vs. Vehicle treated 
mice (n=3). Remodelin has no significant effect (ns) as compared to Vehicle 
treatment and for simplicity in Figure 2 a-d the two have been pooled in one group 
(WT).  
Fig. S4: Engineering and characterisation of a Nat10+/- mouse model. a 
Schematic representation of the gene-trap construct engineered to disrupt the 
Nat10 gene. b The high throughput phenotyping pipeline had n≥337 WT female 
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mice, n≥337 WT male mice, n≥6 Nat10+/- female mice and n≥6 Nat10+/- male mice. 
The exact n number depended on the screen and can be seen in the respective 
excel data files (Supplementary Data file 1). Top: heat-map of adjusted p-value of 
the phenotypic outcomes of the represented assays in Nat10+/- mice compared to 
WT (red: significant parameter; blue: non-significant parameter). A significant 
difference in Klrg1 mature natural killer (Nk) cell number (pa=0.002), Nk cell 
number (pa=0.002) and neutrophil number (pa=0.032) was observed specifically in 
the Nat10+/- males as compared to WT males, but not in females. Raw data are 
presented in Supplementary Data file 1. Bottom: zoom-in on significant parameters 
from the heat-map; Mchc (mean corpuscular hemoglobin concentration); AUC 
(weight area under curve); Mpv (mean platelet volume); Wbc (white blood cells). c 
Gene ontology analysis showing top scoring terms fold enrichment (false discovery 
rate: FDR<0.03; p<0.0005) from genes shown in Fig. 3d. The number of target 
genes in each category is shown. 
Fig. S5: Significant parameters from the heat-map of Nat10+/- mice. From the 
mixed-model analysis, the estimated Nat10+/- genotype effect with 95% confidence 
intervals is shown for significant parameters. Unadjusted p values (pu) and 
adjusted p-values (pa) are represented. The high throughput phenotyping pipeline 
had n≥337 WT female mice, n≥337 WT male mice, n≥6 Nat10+/- female mice and 
n≥6 Nat10+/- male mice. The exact n number depended on the screen and can be 
seen in the respective excel data files (Supplementary Data file 1). a Some 
variables including weight area under the curve (AUC), lean mass, triglycerides, 
cholesterol, total food intake and fat mass showed differences in both males and 
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females. b Other variables including natural killer (NK) cells, neutrophils (number 
and percentage), mean corpuscular hemoglobin concentration (Mchc), potassium, 
monocytes comprising Ly6c negative (Ly6c-) and Ly6c positive (Ly6c+), mean 
platelet volume (Mpv), number of total T cells and white blood cells (Wbc) showed 
sexual dimorphism 
Fig. S6: LmnaG609G/G609G mice have overtly normal sperm and oocytes. a 
Quantification of sperm cells in WT (n=3) and LmnaG609G/G609G (n=3) mice, showing 
no significant difference (p=0.09; two-tailed Student’s t-test). Bar graphs 
representing mean ± SD. b Quantification of in vitro fertilisation potential of sperm 
from WT (n=2) and LmnaG609G/G609G (n=3) male mice using oocytes from WT mice 
and of oocytes from WT (n=4) and LmnaG609G/G609G (n=3) female mice using sperm 
from WT mice. Bar graphs representing mean ± standard deviation. Statistical 
significance was calculated using two-tailed Student’s t-test. c and d Oocytes 
isolated from WT and LmnaG609G/G609G female mice are normal and show normal 
meiotic progression. Representative images show oocytes isolated from 8-week 
old WT and LmnaG609G/G609G female mice. The number of oocytes for each category 
is shown in bottom right-hand corner. Asterisk shows polar body. Scale bars, 20 
µm. e NAT10 inhibition appeared to increase fertility in LmnaG609G/G609G mice but 
was not statistically significant due to low number of mice (p=0.29; two-tailed 
Fisher exact test). 
Fig. S7: Phenotypic characterisation of Lmna+/G609G mice. The high throughput 
phenotyping pipeline had n≥300 WT female mice, n≥300 WT male mice, n≥5 
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Lmna+/G609G female mice and n≥5 Lmna+/G609G male mice. The exact n number 
depended on the screen and can be seen in the respective excel data files 
(Supplementary Data file 4). a Heat-map of adjusted p-values of the phenotypic 
outcomes from the high throughput phenotyping of in Lmna+/G609G mice compared 
to WT (red: significant parameter; blue: non-significant parameter). Raw data and 
statistical output are presented in Supplementary Data file 4. A zoom-in on 
significant parameters from the heat-map is shown. b From the mixed-model 
analysis, the estimated Lmna+/G609G genotype effect with 95% confidence intervals 
is shown for significant variables. Unadjusted p value (pu) and adjusted p-values 
(pa) are represented. Some variables including red cell distribution width, grip 
strength (all paws) and mean corpuscular volume showed sexual dimorphism 
(females-red bars; males blue bars). For the categorical parameters identified as 
significant using the Fisher exact test, such as humerus and tibia, X-ray imaging 
was used to distinguish between normal and abnormal morphology shown as a 
proportion plot. 
Fig. S8: Nat10 depletion reduces back curvature in Lmna+/G609G mice. a 
Images of two littermates at 250 days old. The Lmna+/G609G mouse displayed strong 
back curvature that was not observed in the Lmna+/G609GNat10+/- mouse. b X-ray 
of the indicated mouse genotypes. Arrows indicate back curvature, and show that 
in the heterozygous Lmna+/G609G mice, it is corrected by Nat10 depletion. For WT 
mice, the occurrence of back curvature was rare, while we always see the 
phenotype in Lmna+/G609GNat10+/+ (n=30) and delayed in Lmna+/G609G Nat10+/-
(n=13). 
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Fig. S9: Identification of signatures for Nat10 inhibition in cells and in vivo. 
a Heat map of genes differentially expressed in the heart of LmnaG609G/G609G mice 
(n=2) compared to wild-type (lane 1; n=2) and upon Nat10 reduction (lane 2; n=2) 
or Remodelin treatment (lane 3; n=2). Asterisks indicate genes showing same 
expression level trends in both LmnaG609G/G609GNat10+/- and LmnaG609G/G609G 
Remodelin compared to LmnaG609G/G609G. b Biological term analysis showing top-
scoring terms fold-enrichment (FDR<0.03; p<0.0005) from the genes in row 1 of 
E. The number of target genes in each category is shown. 
Fig. S10: LmnaG609G/G609G mice display increased Lys-40 tubulin acetylation 
that is reduced upon Remodelin treatment. a Representative western blot 
showing that NAT10 inhibition reverses the high tubulin acetylation levels in heart 
tissues from indicated mice and that decrease tubulin acetylation correlates with 
decreased gamma-H2AX phosphorylation. Western blots were repeated more 
than one time on multiple samples. b NAT10 inhibition restores normal levels of 
acetyl-tubulin, as observed by immunohistochemistry in heart sections of 
LmnaG609G/G609G mouse tissues; scale bars being 40μM and 50μM 
respectively. All the immunohistochemistry experiments were performed on 
independent mice (n≥3/genotype). c Representative immunofluorescence images 
of acetyl-tubulin (K40) in aortas; size bar 100µm; dotted white line delineates the 
aorta. Higher magnification snap-shots (red dotted squares) from these images are 
presented alongside quantification in Fig. 5d. d Representative 
immunofluorescence images (left) and quantification (right) of acetyl-tubulin (K40) 
in the coronary arteries of terminal mice of the indicated genotypes and treatment. 
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Size bar 50µm; dotted white line delineates the coronary. Lys-40 (K40) tubulin 
acetylation (green; white arrowheads point to cells that show increased K40-
acetylation) is increased in the LmnaG609G/G609G mice that and significantly 
decreased upon Remodelin treatment (n=3 individual mice; mean ± SD; individual 
data points represented; ns = not significant, *p<0.05; **p<0.01, ***p<0.001; two-
tailed Student’s t-test). 
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Supplementary data files 
Data file 1: Phenotypic analysis of Nat10+/- mice 
Data file 2: RNAseq analysis of heart tissues from Nat10+/- mice  
Data file 3: Phenotypic analysis of LmnaG609G/G609GNat10+/- and Lmna+/G609G 
Nat10+/-mice at 9-12 weeks  
Data file 4: Phenotypic analysis of Lmna+/G609G mice 
Data file 5: RNAseq analysis of heart tissues from LmnaG609G/G609GNat10+/- mice 
and Remodelin treated LmnaG609G/G609G mice 
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Supplementary movie captions 
Movie 1: LmnaG609G/G609G terminal mouse (20% body weight loss; 13-14 weeks 
old) showing premature ageing. The mouse presents rough hair coat, dirty incision, 
squinted eyes, hunched walk and moderate agitation, slight dehydration, pruritic 
and restless. 
Movie 2: LmnaG609G/G609G and LmnaG609G/G609GNat10+/- age matched littermate 
controls at 13 weeks of age. LmnaG609G/G609GNat10+/- mouse (no weight loss; not 
terminal; right side at the beginning of the movie) is fitter than LmnaG609G/G609G 
mouse (20% body weight loss – terminal; left side at the beginning of the movie). 
While the LmnaG609G/G609G mouse is not well groomed, has an awkward gait, is 
slightly hunched and moves slowly, the LmnaG609G/G609GNat10+/- mouse is normal, 
well groomed, alert; active; in good condition and shows normal behavior. 
Movie 3: Terminal LmnaG609G/G609GNat10+/- mice compared to WT littermate 
control. The LmnaG609G/G609GNat10+/- mice (two smaller mice; 20% body weight loss 
– terminal; upper and lower left side at the beginning of the movie) at 15-16 weeks 
of age show no other phenotype than body weight loss as compared to WT 
littermate control (one mouse; lower right side at the beginning of the movie). All 
mice are well groomed, alert; active; in good condition and show normal behavior.  
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Supplementary Tables 
 
Table S1. Design table for the administration of the test articles and sample 
collection in each study group. 
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Table S2. Pharmacokinetics Evaluation of Remodelin via IV and PO administration. 
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Table S3. Comparison of survival rates of mice in this study based on Kaplan-Meyer analysis 
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Supplementary Figures 
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